Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011250 | 0.85 | LMNA (0.54) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL12304883 | 0.83 | LMNA (0.56) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL27922272 | 0.83 | SMN1; SMN2 (0.47) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL27807996 | 0.81 | LMNA (0.54) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL14663780 | 0.81 | POLB (0.61) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL14663614 | 0.80 | POLB (0.56) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL1703134 | 0.80 | LMNA (0.56) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL31174104 | 0.79 | LMNA (0.48) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL28848234 | 0.79 | ALDH1A1 (0.50) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL15547624 | 0.77 | POLB (0.57) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112654605-B | Bridged heterocyclic group substituted pyrimidine compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220348572-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2022-11-03 | — | — | US | disclosed |
| EP-4011865-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2022-06-15 | — | — | EP | disclosed |
| CN-112654605-A | Bridged heterocyclic group substituted pyrimidine compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2021-04-13 | — | — | CN | disclosed |
| WO-2021027647-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2021-02-18 | — | — | WO | disclosed |
| CN-103781780-B | As the heterocyclyl pyrimidines analogue of JAK inhibitor | CELLZOME LTD. (GB) | 2015-11-25 | — | — | CN | disclosed |
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2736901-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| CN-103781780-A | Heterocyclyl pyrimidine analogues as JAK inhibitors | CELLZOME LTD | 2014-05-07 | — | — | CN | disclosed |
| WO-2013014162-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| US-20080269500-A1 | Process for the Preparation of 4-Aminopyrazole Derivatives | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| CN-101268056-A | Process for preparing 4-aminopyrazole derivative | ASTRAZENECA AB (SE) | 2008-09-17 | — | — | CN | disclosed |
| EP-1931639-A2 | PROCESS | Astra Zeneca AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007034183-A2 | PROCESS FOR THE PREPARATION OF 4-AMINOPYRAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | JAK1, JAK3, JAK2 | LMNA 4817/4885MAPT 4232/4885POLB 3863/4885 |
| US-20220348572-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | TYK2, JAK1, JAK2 | LMNA 3975/4885MAPT 3395/4885POLB 1999/4885 |
| US-20080269500-A1 | Process for the Preparation of 4-Aminopyrazole Derivatives | CYP3A4, CYP3A43, CYP3A5 | LMNA 1834/4885MAPT 2108/4885POLB 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.